Sun Pharma Advanced Research Company: Update on litigation – Intimation
Sun Pharma Advanced Research Company (SPARC) filed a disclosure titled "Update on litigation – Intimation". The company is valued at about ₹6,300 crore.
What happened
Sun Pharma Advanced Research Company (SPARC) filed a disclosure with the exchanges on 4 October 2026 at 12:38 PM titled "Update on litigation – Intimation".
Company snapshot
Sun Pharma Advanced Research Company is a small-cap company in the Healthcare sector, with a market value of about ₹6,300 crore.
The stock last traded at ₹194.1, against a 52-week range of ₹108–₹289 (32.8% below the high).
Before this filing the shares had moved −2.7% over the month and −25.8% over three months. Average daily turnover over the last 20 sessions was about ₹19.11 crore.
Promoters held 65.67% at the end of Q1 FY27. Foreign institutions owned 3.90% and domestic institutions 0.09%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 10 | -51.9 | -1.6 |
| Q2 FY26 | 8 | -75.9 | -2.34 |
| Q3 FY26 | 8 | -80.4 | -2.48 |
| Q4 FY26 | 1,853 | 1,762.7 | 54.27 |
| Q1 FY27 | 40 | -20.8 | -0.64 |
What history shows
BCEIE has no earlier litigation filing from this company on record since May 2026.
Across 17 similar disclosures by other Healthcare companies, shares moved −0.5% on average the next day and +0.3% over five days; 35% of them rose the next day.
Market-wide, 531 litigation filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 35% rising.
Past reactions describe what happened before; they are not a forecast.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.